STRO Sutro Biopharma, Inc. - Common Stock
$22,16
Preço · Ago 18, 2026
Fundamentais a partir de Ago 12, 2026
Intervalo 52 Semanas
$1–$44
50% of range
Classificação do Analista
BUY
19 analysts
Preço-Alvo
$48
+116% upside
P/E (TTM)
-1.0
ROE
232.2%
Margem de Lucro Líquido
-186.5%
Sobre Sutro Biopharma, Inc. - Common Stock Visão geral da empresa da Wikipedia
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Ler mais
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.
As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically validated targets for which the current standard of care is suboptimal.
Technology
Sutro's Xpress CF Platform is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology. XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins. The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs). Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.
Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over US$170 million in capital.
Collaborations
In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced they had refocused their 2014 immuno-oncology collaboration on four programs advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).
Awards
The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014. In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
STRO Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$22.16
Capitalização de Mercado
$190M
P/E (TTM)
-1.0
EPS (TTM)
$-22.49
Receita (TTM)
$102M
Rendimento div.
—
ROE
232.2%
Dívida/Capital
—
Intervalo 52 Semanas
$1 – $44
STRO Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$102M
2016-12-31
→
2025-12-31
EPS
$-22.49
2020-12-31
→
2025-12-31
Fluxo de caixa livre
—
2018-12-31
→
2018-12-31
Margens
-186.5%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
STRO
Mediana de Pares
P/E (TTM)
-1.0
6.1
P/S (TTM)
1.9
7.7
P/B
-1.4
2.2
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
STRO
Mediana de Pares
Operating Margin (Margem Operacional)
-154.5%
—
Net Profit Margin (Margem de Lucro Líquido)
-186.5%
-60.9%
ROA
-68.1%
-50.0%
ROE
232.2%
-44.8%
ROIC
119.5%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
STRO
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
2.0
5.9
Quick Ratio (Índice de Liquidez Seca)
1.9
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
STRO
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
65.2%
—
Revenue CAGR 3Y (CAGR Receita 3A)
14.8%
—
Revenue CAGR 5Y (CAGR Receita 5A)
19.1%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
STRO
Mediana de Pares
STRO Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
19 analistas
- Compra forte 5 26,3%
- Compra 12 63,2%
- Manter 1 5,3%
- Venda 1 5,3%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
13 analistas · 2026-08-13
Mediana
$50.00
Agora
$22.16
Mín
$10.00
Máx
$61.00
Alvo mediano
$50.00
+125,6%
Alvo médio
$47.77
+115,6%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.34%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 31 de Março de 2026 | $-2.94 | $-3.85 | 0.91% |
| 31 de Dezembro de 2025 | $-5.29 | $-4.43 | -0.86% |
| 30 de Setembro de 2025 | $-6.70 | $-4.23 | -2.5% |
| 30 de Junho de 2025 | $-1.40 | $-4.10 | 2.7% |
| 31 de Março de 2025 | $-9.10 | $-7.22 | -1.9% |
| 31 de Dezembro de 2024 | $-8.90 | $-8.48 | -0.42% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| STRO | $99M | -0.5 | 65.2% | -186.5% | 232.2% | — |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | — |
| DMAC | $428M | — | — | — | -78.7% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | — |
| SABS | — | — | — | — | — | — |
| ABEO | $290M | 5.2 | 147.5% | 1223.1% | 44.1% | — |
| IMRX | — | -5.2 | — | — | -45.3% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | |
| R&D Expense | $166M | $252M | $180M | $137M | $104M | $77M | $66M | $54M | $55M | |
| SG&A Expense | $41M | $48M | $63M | $60M | $56M | $37M | $33M | $21M | $16M | |
| Operating Expenses | $261M | $300M | $243M | $197M | $160M | $114M | $98M | $76M | $71M | |
| Operating Income | $-158M | $-238M | $-89M | $-129M | $-99M | $-71M | $-55M | $-37M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $612.0K | |
| Other Non-op | · | · | · | · | · | · | · | $2M | $-77.0K | |
| Pretax Income | $-191M | $-225M | $-89M | $-117M | $-106M | $-32M | · | · | · | |
| Income Tax | $-93.0K | $2M | $18M | $2M | $0 | $103.0K | $0 | $0 | $0 | |
| Net Income | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | $-20M | |
| EPS (Basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| EPS (Diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | · | · | · | |
| Shares (Basic) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| Shares (Diluted) | 8,497,798 | 7,736,734 | 60,163,542 | 50,739,185 | 46,119,089 | 32,573,469 | · | · | · | |
| EBITDA | $-151M | $-231M | $-82M | $-123M | $-94M | $-67M | · | $-33M | · |
Balanço Patrimonial 24
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $190M | $69M | $47M | $30M | $206M | $5M | $125M | $22M | |
| Short-term Investments | $83M | $127M | $264M | $255M | $130M | $120M | $113M | $79M | · | |
| Receivables | $4M | $9M | $36M | $7M | $12M | $6M | $6M | $2M | $2M | |
| Prepaid Expense | $6M | $18M | $10M | $12M | $8M | $4M | $4M | $3M | $2M | |
| Current Assets | $151M | $343M | $422M | $353M | $219M | $378M | $129M | $210M | $26M | |
| PP&E (Net) | $11M | $18M | $22M | $25M | $23M | $13M | $10M | $11M | $14M | |
| PP&E (Gross) | $38M | $67M | $64M | $63M | $56M | $50M | $43M | $40M | $39M | |
| Accum. Depreciation | $27M | $49M | $42M | $38M | $33M | $37M | $34M | $29M | $25M | |
| Other Non-current Assets | $495.0K | $7M | $4M | $2M | $2M | $2M | $3M | $2M | $1M | |
| Total Assets | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Accounts Payable | $8M | $10M | $9M | $5M | $6M | $6M | $6M | $3M | $3M | |
| Accrued Liabilities | $15M | $13M | $15M | $13M | $11M | $9M | $6M | $6M | $4M | |
| Current Liabilities | $75M | $132M | $94M | $67M | $42M | $30M | $33M | $36M | $32M | |
| Capital Leases | $8M | $16M | $23M | $30M | $31M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $119.0K | $146.0K | $481.0K | $134.0K | $102.0K | $14.0K | |
| Total Liabilities | $306M | $343M | $321M | $190M | $89M | $62M | $59M | $92M | $47M | |
| Long-term Debt | · | · | $4M | $16M | $25M | $25M | · | $15M | · | |
| Total Debt | · | · | $4M | $16M | $25M | $25M | · | $10M | · | |
| Common Stock | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K | $46.0K | $23.0K | $23.0K | · | |
| Retained Earnings | $-978M | $-787M | $-559M | $-453M | $-333M | $-228M | $-196M | $-150M | $-115M | |
| AOCI | $19.0K | $39.0K | $21.0K | $-618.0K | $-314.0K | $129.0K | $165.0K | $-47.0K | · | |
| Stockholders' Equity | $-132M | $45M | $150M | $217M | $253M | $332M | $98M | $132M | $-109M | |
| Liabilities + Equity | $174M | $387M | $471M | $407M | $341M | $394M | $156M | $223M | $41M | |
| Shares Outstanding | 8,584,309 | 8,306,398 | 61,009,829 | 57,499,541 | 46,327,131 | 45,752,116 | 23,098,969 | 22,848,184 | 465,330 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $7M | $6M | $5M | $4M | $5M | $5M | $5M | |
| Stock-based Comp | $14M | $25M | $25M | $26M | $23M | $12M | $10M | $3M | $1M | |
| Restructuring | $13M | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-7M | $4M | $-37M | $91M | $-4M | $-52M | · | $41M | · | |
| Operating Cash Flow | $-177M | $-192M | $-112M | $4M | $-82M | $-68M | $-65M | $13M | $-37M | |
| CapEx | · | · | · | · | · | · | · | $2M | $3M | |
| Investing Cash Flow | $45M | $219M | $-4M | $-35M | $-97M | $604.0K | $-51M | $-80M | $33M | |
| Debt Issued | · | · | · | · | · | · | · | $0 | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | $0 | $25M | $0 | $0 | · | $251M | $-327.0K | · | · | |
| Stock Repurchased | · | · | · | · | $7.0K | · | · | · | · | |
| Net Stock Activity | $0 | $25M | $12M | $56M | $-7.0K | $251M | · | · | · | |
| Financing Cash Flow | $44.0K | $94M | $138M | $48M | $3M | $269M | $-4M | $171M | $15M | |
| Net Change in Cash | $-132M | $121M | $22M | $17M | $-176M | $202M | $-120M | $103M | $10M | |
| Taxes Paid | $75.0K | $18M | $379.0K | $0 | $103.0K | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | $11M | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | · | -96.9% | · | |
| Net Margin | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | · | -91.9% | · | |
| Pretax Margin | -186.5% | -362.8% | -57.6% | -172.2% | · | · | · | · | · | |
| EBITDA Margin | -147.4% | -372.7% | -53.6% | -181.9% | -151.4% | -156.3% | · | -85.1% | · | |
| ROA | -68.1% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | · | -26.8% | · | |
| ROE | 232.2% | -292.0% | -81.5% | -53.4% | -39.4% | -11.2% | · | 713.8% | · | |
| ROIC | 119.5% | -540.2% | -70.0% | -56.5% | · | · | · | · | · |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 | 12.8 | · | 5.8 | · | |
| Quick Ratio | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 | 11.2 | · | 5.7 | · | |
| Debt / Equity | · | · | 0.0 | 0.1 | 0.1 | 0.1 | · | 0.1 | · | |
| LT Debt / Equity | · | · | 0.0 | 0.0 | 0.1 | 0.1 | · | 0.1 | · | |
| Interest Coverage | · | · | · | · | · | · | · | -22.9 | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | |
| Receivables Turnover | 16.3 | 2.8 | 7.1 | 6.9 | 6.9 | 7.2 | · | 18.7 | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | -59.6% | 126.8% | 9.5% | 44.8% | · | · | · | · | |
| Revenue CAGR 3Y | 14.8% | 0.09% | 53.2% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.1% | · | · | · | · | · | · | · | · |
Avaliação (TTM) 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | · | |
| Net Income TTM | $-191M | $-227M | $-107M | $-119M | $-106M | $-32M | $-119M | $-35M | · | |
| Market Cap | $99M | $152M | $262M | $465M | $689M | $993M | · | $206M | · | |
| Enterprise Value | · | · | $-68M | $179M | $554M | $691M | · | $12M | · | |
| P/E | -0.5 | -0.1 | -2.4 | -3.4 | -6.5 | -21.9 | · | · | · | |
| P/S | 1.0 | 2.4 | 1.7 | 6.9 | 11.1 | 23.2 | · | 5.4 | · | |
| P/B | -0.7 | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | 1.6 | · | |
| P / Tangible Book | · | 3.4 | 1.7 | 2.1 | 2.7 | 3.0 | · | · | · | |
| P / Cash Flow | -0.6 | -0.8 | -2.3 | 130.9 | -8.4 | -14.6 | · | 16.2 | · | |
| P / FCF | · | · | · | · | · | · | · | 18.5 | · | |
| EV / EBITDA | · | · | 0.8 | -1.4 | -5.9 | -10.4 | · | -0.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | 1.0 | · | |
| EV / Revenue | · | · | -0.4 | 2.6 | 8.9 | 16.2 | · | 0.3 | · | |
| Earnings Yield | -194.4% | -1597.8% | -41.5% | -29.1% | -15.4% | -4.6% | · | · | · |
Demonstração de Resultados 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $12M | $10M | $64M | $17M | $15M | $9M | $26M | $13M | $114M | $17M | $10M | $13M | $9M | $25M | |
| R&D Expense | $32M | $37M | $37M | $40M | $38M | $52M | $71M | $62M | $62M | $57M | $54M | $46M | $42M | $39M | $43M | $32M | |
| SG&A Expense | $8M | $8M | $9M | $9M | $10M | $13M | $9M | $14M | $12M | $13M | $17M | $15M | $15M | $16M | $15M | $15M | |
| Operating Expenses | $40M | $44M | $50M | $58M | $67M | $86M | $80M | $76M | $74M | $70M | $71M | $61M | $57M | $55M | $58M | $46M | |
| Operating Income | $-30M | $-30M | $-38M | $-48M | $-3M | $-69M | $-65M | $-68M | $-49M | $-57M | $43M | $-44M | $-46M | $-42M | $-49M | $-21M | |
| Pretax Income | $-39M | $-38M | $-47M | $-57M | $-12M | $-76M | $-70M | $-49M | $-48M | $-58M | $47M | $-47M | $-38M | $-50M | $-35M | $-19M | |
| Income Tax | $1.0K | $-15.0K | $-82.0K | $0 | $-18.0K | $7.0K | $2M | $0 | $8.0K | · | $16M | $2M | $151.0K | $395.0K | $0 | $0 | |
| Net Income | $-39M | $-38M | $-47M | $-57M | $-11M | $-76M | $-72M | $-49M | $-48M | $-58M | $31M | $-49M | $-39M | $-50M | $-35M | $-19M | |
| EPS (Basic) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| EPS (Diluted) | $-2.33 | $-2.94 | $-20.77 | $-0.67 | $-1.35 | $-9.08 | $-27.63 | $-0.59 | $-0.59 | $-0.59 | $0.52 | $-0.81 | $-0.64 | $-0.85 | $-0.59 | $-0.37 | |
| Shares (Basic) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| Shares (Diluted) | 16,571,602 | 13,082,355 | -244,058,204 | 84,869,864 | 8,511,985 | 8,364,294 | -216,989,358 | 82,043,671 | 81,224,628 | 61,457,793 | -119,498,390 | 60,599,025 | 60,339,475 | 58,723,432 | -95,063,345 | 52,345,732 | |
| EBITDA | $-30M | $-28M | · | $-48M | $-3M | $-67M | · | $-68M | $-49M | $-55M | · | $-44M | $-46M | $-41M | · | $-21M |
Balanço Patrimonial 23
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $74M | $58M | $66M | $64M | $106M | $190M | $175M | $91M | $65M | $69M | $82M | $235M | $62M | $47M | $97M | |
| Short-term Investments | $110M | $129M | $83M | $102M | $141M | $143M | $127M | $214M | $285M | $202M | $264M | $239M | $123M | $189M | · | $191M | |
| Receivables | $6M | $12M | $4M | $4M | $8M | $14M | $9M | $7M | $7M | $31M | $36M | $17M | $10M | $10M | · | $11M | |
| Prepaid Expense | $6M | $6M | $6M | $11M | $18M | $25M | $18M | $11M | $11M | $10M | $10M | $9M | $10M | $18M | · | $11M | |
| Current Assets | $176M | $221M | $151M | $182M | $232M | $287M | $343M | $406M | $443M | $355M | $422M | $381M | $412M | $304M | · | $347M | |
| PP&E (Net) | $8M | $9M | $11M | $13M | $15M | $17M | $18M | $19M | $19M | $21M | $22M | $22M | $24M | $24M | · | $24M | |
| PP&E (Gross) | · | · | $38M | · | · | · | $67M | · | · | · | $64M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $27M | · | · | · | $49M | · | · | · | $42M | · | · | · | · | · | |
| Other Non-current Assets | $1M | $1M | $495.0K | $0 | $50.0K | $85.0K | $7M | $7M | $5M | $6M | $4M | $3M | $3M | $3M | · | $2M | |
| Total Assets | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Accounts Payable | $3M | $5M | $8M | $7M | $4M | $8M | $10M | $6M | $6M | $8M | $9M | $6M | $4M | $5M | · | $12M | |
| Accrued Liabilities | $6M | $5M | $15M | $13M | $12M | $12M | $13M | $13M | $10M | $7M | $15M | $11M | $10M | $6M | · | $10M | |
| Current Liabilities | $53M | $71M | $75M | $72M | $74M | $133M | $132M | $131M | $130M | $80M | $94M | $74M | $67M | $59M | · | $58M | |
| Capital Leases | $4M | $6M | $8M | $10M | $12M | $14M | $16M | $18M | $20M | $21M | $23M | $25M | $27M | $28M | · | $31M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | · | · | $133.0K | |
| Total Liabilities | $298M | $309M | $306M | $297M | $294M | $347M | $343M | $341M | $337M | $305M | $321M | $319M | $310M | $173M | · | $171M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $7M | |
| Common Stock | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K | $82.0K | $62.0K | $61.0K | $61.0K | $60.0K | $60.0K | · | $55.0K | |
| Retained Earnings | $-1.05B | $-1.02B | $-978M | $-931M | $-874M | $-863M | $-787M | $-714M | $-666M | $-618M | $-559M | $-590M | $-541M | $-503M | · | $-418M | |
| AOCI | $-58.0K | $-101.0K | $19.0K | $33.0K | $-13.0K | $-9.0K | $39.0K | $106.0K | $-163.0K | $-113.0K | $21.0K | $7.0K | $16.0K | $-107.0K | · | $-1M | |
| Stockholders' Equity | $-103M | $-67M | $-132M | $-87M | $-32M | $-26M | $45M | $111M | $152M | $98M | $150M | $112M | $155M | $185M | $217M | $230M | |
| Liabilities + Equity | $194M | $242M | $174M | $210M | $262M | $321M | $387M | $452M | $489M | $403M | $471M | $432M | $465M | $358M | · | $401M | |
| Shares Outstanding | 16,576,205 | 16,566,803 | 8,584,309 | 85,101,749 | 84,720,047 | 84,349,041 | 8,306,398 | 82,395,350 | 81,861,584 | 62,456,546 | 61,009,829 | 60,900,704 | 60,471,041 | 60,161,801 | · | 54,631,360 |
Fluxo de Caixa 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $5M | $6M | $6M | $7M | $6M | $6M | $6M | $6M | $7M | $6M | $6M | $7M | |
| Restructuring | · | $0 | $1M | $3M | $1M | $8M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-7M | · | · | · | $647.0K | · | · | · | $-14M | · | · | · | $-19M | · | · | |
| Operating Cash Flow | $-38M | $-42M | $-26M | $-38M | $-45M | $-68M | $-72M | $-65M | $9M | $-65M | $14M | $-34M | $-31M | $-61M | $-24M | $66M | |
| Investing Cash Flow | $19M | $-45M | $19M | $40M | $3M | $-16M | $87M | $147M | $-80M | $64M | $-24M | $-114M | $66M | $67M | $-38M | $-78M | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-418.0K | $103M | $-64.0K | $102.0K | $-60.0K | $66.0K | $-24.0K | $1M | $96M | $-3M | $-3M | $-6M | $138M | $9M | $12M | $30M | |
| Net Change in Cash | $-19M | $16M | $-8M | $2M | $-42M | $-84M | $16M | $84M | $26M | $-4M | $-13M | $-153M | $173M | $15M | $-50M | $18M | |
| Taxes Paid | $1.0K | $-15.0K | $64.0K | $0 | $4.0K | $7.0K | $2M | $2.0K | $15M | $10.0K | · | · | · | · | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -303.8% | -204.2% | · | -499.9% | -5.2% | -393.8% | · | -797.2% | -189.4% | -435.1% | · | -260.1% | -443.5% | -333.3% | · | -84.3% | |
| Net Margin | -391.6% | -265.0% | · | -586.6% | -18.0% | -436.6% | · | -572.6% | -186.8% | -447.5% | · | -291.2% | -370.0% | -394.9% | · | -77.5% | |
| Pretax Margin | -391.6% | -265.1% | · | -586.6% | -18.1% | · | · | -572.6% | -186.8% | -447.5% | · | -280.3% | -368.6% | -391.8% | · | -77.5% | |
| EBITDA Margin | -303.8% | -195.4% | · | -499.9% | -5.2% | -382.9% | · | -797.2% | -189.4% | -421.5% | · | -260.1% | -443.5% | -320.5% | · | -84.3% | |
| ROA | -16.9% | -13.7% | · | -17.2% | -3.1% | -21.0% | · | -11.0% | -10.1% | -15.3% | · | -11.8% | -9.1% | -15.1% | · | -5.1% | |
| ROE | 56.9% | 83.0% | · | -474.8% | -19.1% | -210.4% | · | -43.6% | -31.3% | -41.1% | · | -28.8% | -21.2% | -24.7% | · | -7.6% | |
| ROIC | 28.9% | 44.3% | · | 55.5% | 10.4% | · | · | -61.1% | -32.0% | · | · | -40.7% | -30.0% | -23.0% | · | · |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.1 | · | 2.5 | 3.1 | 2.2 | · | 3.1 | 3.4 | 4.5 | · | 5.2 | 6.1 | 5.1 | · | 5.9 | |
| Quick Ratio | 3.2 | 3.0 | · | 2.4 | 2.9 | 2.0 | · | 3.0 | 2.9 | 3.8 | · | 4.6 | 5.5 | 4.4 | · | 5.1 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.0 | 0.2 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Receivables Turnover | 1.4 | 1.1 | · | 1.8 | 8.5 | 0.8 | · | 0.7 | 3.0 | 0.6 | · | 1.2 | 0.2 | 1.2 | · | 2.1 |
Avaliação (TTM) 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $105M | · | $99M | $115M | $65M | · | $64M | $66M | $53M | · | $65M | $76M | $72M | · | $68M | |
| Net Income TTM | $-145M | $-183M | · | $-193M | $-184M | $-231M | · | $-204M | $-194M | $-196M | · | $-157M | $-134M | $-135M | · | $-116M | |
| Market Cap | $550M | $413M | · | $74M | $60M | $55M | · | $285M | $240M | $353M | · | $211M | $281M | $278M | · | $303M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $23M | |
| P/E | -4.6 | -1.9 | · | -0.4 | -0.3 | -0.2 | · | -1.3 | -1.1 | -2.0 | · | -1.3 | -1.9 | -1.8 | · | -2.3 | |
| P/S | 5.6 | 3.9 | · | 0.7 | 0.5 | 0.8 | · | 4.4 | 3.6 | 6.7 | · | 3.2 | 3.7 | 3.9 | · | 4.5 | |
| P/B | -5.3 | -6.2 | · | -0.8 | -1.9 | -2.1 | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Tangible Book | · | · | · | · | · | · | · | 2.6 | 1.6 | 3.6 | · | 1.9 | 1.8 | 1.5 | · | 1.3 | |
| P / Cash Flow | · | -9.8 | · | · | · | -0.8 | · | · | · | -5.5 | · | · | · | -4.6 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -1.1 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.3 | |
| Earnings Yield | -22.0% | -51.5% | · | -265.5% | -314.1% | -412.3% | · | -74.6% | -89.8% | -51.1% | · | -77.0% | -51.8% | -56.5% | · | -43.8% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $102M | $62M | $154M | $68M | $62M |
| Margem Operacional % | -154.5% | -384.3% | -58.1% | -190.3% | -159.2% |
| Lucro líquido | $-191M | $-227M | $-107M | $-119M | $-106M |
| EPS Diluído | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | — | — | 0.0 | 0.1 | 0.1 |
| Índice de liquidez corrente | 2.0 | 2.6 | 4.5 | 5.3 | 5.2 |
| Índice de Liquidez Seca | 1.9 | 2.5 | 3.9 | 4.7 | 4.2 |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 111 declarantes · $467.3M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 46 (+21 vs trimestre anterior) | 16 (+8 vs trimestre anterior) | 20 (0 vs trimestre anterior) | 19 (+5 vs trimestre anterior) | +1.3M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | $43.320.887 | 1.304.846 | 9,27% | Ações |
| BVF INC/IL | $41.559.362 | 1.251.788 | 8,89% | Ações |
| Affinity Asset Advisors, LLC | $38.926.568 | 1.172.487 | 8,33% | Ações |
| SAMSARA BIOCAPITAL, LLC | $35.287.350 | 1.062.872 | 7,55% | Ações |
| Kynam Capital Management, LP | $28.968.926 | 872.558 | 6,20% | Ações |
| ORBIMED ADVISORS LLC | $24.698.941 | 743.944 | 5,29% | Ações |
| Balyasny Asset Management L.P. | $23.610.578 | 711.162 | 5,05% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.048.071 | 694.219 | 4,93% | Ações |
| EVENTIDE ASSET MANAGEMENT, LLC | $19.430.698 | 585.262 | 4,16% | Ações |
| Velan Capital Investment Management LP | $17.003.712 | 512.160 | 3,64% | Ações |
| Woodline Partners LP | $15.206.563 | 458.029 | 3,25% | Ações |
| ADAR1 Capital Management, LLC | $13.413.265 | 404.014 | 2,87% | Ações |
| MILLENNIUM MANAGEMENT LLC | $12.150.270 | 365.972 | 2,60% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $11.027.500 | 332.057 | 2,36% | Ações |
| STATE STREET CORP | $10.158.503 | 305.979 | 2,17% | Ações |
| Merck & Co., Inc. | $9.042.053 | 272.351 | 1,93% | Ações |
| ACUTA CAPITAL PARTNERS, LLC | $8.972.333 | 270.251 | 1,92% | Ações |
| AMERIPRISE FINANCIAL INC | $8.123.011 | 244.669 | 1,74% | Ações |
| Point72 Asset Management, L.P. | $7.895.856 | 237.827 | 1,69% | Ações |
| KVP Capital Advisors, LP | $7.522.290 | 226.575 | 1,61% | Ações |
| TWO SIGMA INVESTMENTS, LP | $6.696.042 | 201.688 | 1,43% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.559.058 | 197.562 | 1,40% | Ações |
| UBS Group AG | $5.407.251 | 162.869 | 1,16% | Ações |
| Seven Fleet Capital Management LP | $3.794.182 | 159.118 | 0,81% | Ações |
| Qube Research & Technologies Ltd | $3.539.452 | 106.610 | 0,76% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $3.460.502 | 104.232 | 0,74% | Ações |
| CITADEL ADVISORS LLC | $3.385.205 | 101.964 | 0,72% | Ações |
| MACKENZIE FINANCIAL CORP | $3.146.264 | 94.767 | 0,67% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $2.865.957 | 86.324 | 0,61% | Ações |
| MARSHALL WACE, LLP | $2.448.865 | 73.761 | 0,52% | Ações |
| Y-Intercept (Hong Kong) Ltd | $1.855.183 | 55.879 | 0,40% | Ações |
| Squarepoint Ops LLC | $1.843.895 | 55.539 | 0,39% | Ações |
| XTX Topco Ltd | $1.732.011 | 52.169 | 0,37% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.636.826 | 49.302 | 0,35% | Ações |
| Sigma Planning Corp | $1.494.664 | 45.020 | 0,32% | Ações |
| Fisher Asset Management, LLC | $1.171.794 | 35.295 | 0,25% | Ações |
| Elmind Capital, LP | $1.063.628 | 32.037 | 0,23% | Ações |
| D. E. Shaw & Co., Inc. | $1.000.250 | 30.128 | 0,21% | Ações |
| GOLDMAN SACHS GROUP INC | $975.814 | 29.392 | 0,21% | Ações |
| Trexquant Investment LP | $917.515 | 27.636 | 0,20% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $909.116 | 27.383 | 0,19% | Ações |
| BANK OF AMERICA CORP /DE/ | $863.897 | 26.021 | 0,18% | Ações |
| RHUMBLINE ADVISERS | $684.845 | 20.628 | 0,15% | Ações |
| JPMORGAN CHASE & CO | $625.079 | 18.743 | 0,13% | Ações |
| BlackRock, Inc. | $595.276 | 17.930 | 0,13% | Ações |
| SEI INVESTMENTS CO | $544.048 | 16.387 | 0,12% | Ações |
| Informed Momentum Co LLC | $538.902 | 16.232 | 0,12% | Ações |
| DEUTSCHE BANK AG\ | $516.692 | 15.563 | 0,11% | Ações |
| RBF Capital, LLC | $507.030 | 15.272 | 0,11% | Ações |
| WELLS FARGO & COMPANY/MN | $449.661 | 13.544 | 0,10% | Ações |
| AJU IB Investment Co., Ltd. | $435.925 | 17.500 | 0,09% | Ações |
| Bank of New York Mellon Corp | $434.522 | 13.088 | 0,09% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $368.520 | 11.100 | 0,08% | Opção de compra |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $365.200 | 11.000 | 0,08% | Opção de venda |
| MetLife Investment Management, LLC | $312.113 | 9.401 | 0,07% | Ações |
| Walleye Capital LLC | $308.959 | 9.306 | 0,07% | Ações |
| Integrated Quantitative Investments LLC | $296.775 | 8.939 | 0,06% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $279.743 | 8.426 | 0,06% | Ações |
| Lighthouse Investment Partners, LLC | $277.818 | 8.368 | 0,06% | Ações |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $242.792 | 7.313 | 0,05% | Ações |
| ALLIANCEBERNSTEIN L.P. | $242.360 | 7.300 | 0,05% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $232.433 | 7.001 | 0,05% | Ações |
| Persistent Asset Partners Ltd | $218.091 | 6.569 | 0,05% | Ações |
| CITIGROUP INC | $216.995 | 6.536 | 0,05% | Ações |
| Verdad Advisers, LP | $212.480 | 6.400 | 0,05% | Ações |
| Invesco Ltd. | $211.119 | 6.359 | 0,05% | Ações |
| HSBC HOLDINGS PLC | $205.722 | 6.234 | 0,04% | Ações |
| TWO SIGMA ADVISERS, LP | $203.401 | 17.580 | 0,04% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $185.920 | 5.600 | 0,04% | Ações |
| MORGAN STANLEY | $181.870 | 5.478 | 0,04% | Ações |
| Vanguard Global Advisers, LLC | $180.774 | 5.445 | 0,04% | Ações |
| Police & Firemen's Retirement System of New Jersey | $156.173 | 4.704 | 0,03% | Ações |
| Nuveen, LLC | $131.837 | 3.971 | 0,03% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $119.520 | 3.600 | 0,03% | Ações |
| Nuveen Asset Management, LLC | $103.678 | 56.347 | 0,02% | Ações |
| BARCLAYS PLC | $84.228 | 2.537 | 0,02% | Ações |
| NORTHERN TRUST CORP | $83.100 | 2.503 | 0,02% | Ações |
| State of Wyoming | $53.718 | 1.618 | 0,01% | Ações |
| Legal & General Group Plc | $51.394 | 1.548 | 0,01% | Ações |
| Ameritas Investment Partners, Inc. | $48.074 | 1.448 | 0,01% | Ações |
| FMR LLC | $44.388 | 1.337 | 0,01% | Ações |
| Russell Investments Group, Ltd. | $42.330 | 1.275 | 0,01% | Ações |
| VANGUARD GROUP INC | $36.307 | 3.138 | 0,01% | Ações |
| Tower Research Capital LLC (TRC) | $28.751 | 866 | 0,01% | Ações |
| Point72 Asia (Singapore) Pte. Ltd. | $26.943 | 31.026 | 0,01% | Ações |
| CWM, LLC | $24.487 | 983 | 0,01% | Ações |
| ROYAL BANK OF CANADA | $23.000 | 687 | 0,00% | Ações |
| Owl Creek Wealth Partners LLC | $16.302 | 491 | 0,00% | Ações |
| ACADIAN ASSET MANAGEMENT LLC | $12.405 | 373.839 | 0,00% | Ações |
| Sterling Capital Management LLC | $9.329 | 281 | 0,00% | Ações |
| Quantbot Technologies LP | $6.673 | 201 | 0,00% | Ações |
| Physician Wealth Advisors, Inc. | $6.043 | 182 | 0,00% | Ações |
| MERCER GLOBAL ADVISORS INC /ADV | $3.718 | 112 | 0,00% | Ações |
| OSAIC HOLDINGS, INC. | $3.320 | 100 | 0,00% | Ações |
| PNC Financial Services Group, Inc. | $2.058 | 62 | 0,00% | Ações |
| Fortitude Family Office, LLC | $1.859 | 56 | 0,00% | Ações |
| Bogart Wealth, LLC | $1.660 | 50 | 0,00% | Ações |
| Parallel Advisors, LLC | $1.560 | 47 | 0,00% | Ações |
| NISA INVESTMENT ADVISORS, LLC | $1.461 | 44 | 0,00% | Ações |
| Accredited Wealth Management, LLC | $869 | 5 | 0,00% | Ações |
Executivos da empresa 27 insiders · 14 diretores · 14 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| William J Newell | CEO | 3 de Março de 2023 M | 164.816 | 0 | 0 | $0 |
| Gregory K. Chow | CFO | 2 de Junho de 2026 M | 4.725 | 0 | 0 | $0 |
| Edward C Albini | CFO and Secretary | 3 de Março de 2023 M | 87.693 | 0 | 0 | $0 |
| Jane Chung | President and COO | 1 de Dezembro de 2023 A | 31.698 | 0 | 0 | $0 |
| Hans-Peter Gerber | Chief Scientific Officer | 18 de Setembro de 2023 A | — | 0 | 0 | $0 |
| Brunilda Shtylla | Chief Business Officer | 28 de Agosto de 2023 S | 0 | 0 | 0 | $0 |
| Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | 12 de Julho de 2023 M | 24.988 | 0 | 0 | $0 |
| Venkatesh Srinivasan | Chief Tech Op Officer | 1 de Maio de 2023 A | — | 0 | 0 | $0 |
| Trevor Hallam | Pres. Rsrch & Cf. Sctific Ofcr | 14 de Abril de 2023 M | 100.368 | 0 | 0 | $0 |
| Anne Elizabeth Borgman | Chief Medical Officer | 15 de Março de 2023 A | — | 0 | 0 | $0 |
| Anik Shabbir | Chief Technical Ops. Officer | 3 de Março de 2023 M | 40.827 | 0 | 0 | $0 |
| Linda A Fitzpatrick | Chief People & Comm. Officer | 3 de Março de 2023 M | 52.690 | 0 | 0 | $0 |
| Arturo Molina MD | Chief Medical Officer | 5 de Março de 2022 M | 37.736 | 0 | 0 | $0 |
| Stephen Worsley | Chief Business Officer | 29 de Janeiro de 2019 A | — | 0 | 0 | $0 |
| Heidi Hunter | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Michael Dybbs | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Jon Marc Wigginton | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Sukhi Jagpal | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Joseph M Lobacki | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| Daniel H Petree | Conselheiro | 5 de Junho de 2026 A | 18.601 | 0 | 0 | $0 |
| Connie Matsui | Conselheiro | 5 de Junho de 2026 A | 50.000 | 1 | 0 | $40.000 |
| James P Panek | Conselheiro | 5 de Junho de 2026 A | — | 0 | 0 | $0 |
| John Gordon Freund | Conselheiro | 8 de Junho de 2023 A | 56.327 | 0 | 0 | $0 |
| Shalini Sharp | Conselheiro | 6 de Junho de 2022 A | — | 0 | 0 | $0 |
| Daniel Janney | Conselheiro | 17 de Junho de 2019 A | 1.944.901 | 0 | 0 | $0 |
| Michael Jay Ross | Conselheiro | 1 de Outubro de 2018 C | 18.248 | 0 | 0 | $0 |
| Bryan V Lawlis | Conselheiro | 26 de Setembro de 2018 A | — | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 1 participação
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., ILSF III, LLC, International Life Sciences Fund III (GP), L.P., International Life Sciences Fund III Co-Investment, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Strategic Partners, L.P. | 9 de Outubro de 2018 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 15 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 3.826 SH | 8 de Agosto de 2026 | Diário |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,25% | 28.745 SH | 8 de Agosto de 2026 | Diário |
| IWC · iShares Trust | 0,09% | 54.216 SH | 8 de Agosto de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 11.715 SH | 8 de Agosto de 2026 | Diário |
| IWN · iShares Trust | 0,02% | 121.308 SH | 8 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 91.894 SH | 8 de Agosto de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 16.520 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,01% | 398.610 SH | 8 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 177.152 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,01% | 47.358 SH | 8 de Agosto de 2026 | Diário |
| IWO · iShares Trust | 0,00% | 22.665 SH | 8 de Agosto de 2026 | Diário |
| ITOT · iShares Trust | 0,00% | 29.451 SH | 8 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 501.524 SH | 8 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.670 SH | 8 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.330 SH | 8 de Agosto de 2026 | Diário |